title: [Neovascular membrane and pregnancy. Treatment with bevacizumab].
abstract: METHODS
  Female in her sixth month of pregnancy, with a history of refractive surgery, who consulted due to a metamorphopsia and decrease in visual acuity in the right eye. A presumed ocular histoplasmosis syndrome (POHS) and a subfoveal choroidal neovascular membrane were observed in the fundoscopy. Two monthly doses of intravitreal bevacizumab were given after the labour, but the third dose was never inyected as the patient became pregnant again. She subsequently had a spontaneous miscarriage.
  
  
  CONCLUSIONS
  Treatment with intravitreal bevacizumab during pregnancy is controversial as it may increase the risk of miscarriage during the first trimester.
authors: Servicio de Oftalmología, Hospital Universitario Virgen de la Vega, Salamanca, España. igomezledesma@yahoo.com
authors: I
authors: I
authors: Gómez Ledesma
authors: M Á
authors: MÁ
authors: de Santiago Rodríguez
authors: I
authors: I
authors: Follana Neira
authors: F
authors: F
authors: León Garrigosa
mesh_terms: D000022:Abortion, Spontaneous / Q000139:chemically induced*; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D000075202:Contraindications; D015821:Eye Infections, Fungal / Q000150:complications* / Q000175:diagnosis; D005260:Female; D006660:Histoplasmosis / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D058449:Intravitreal Injections; D020731:Keratomileusis, Laser In Situ; D011183:Postoperative Complications; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis*; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis; D011261:Pregnancy Trimester, First; D011644:Puerperal Disorders / Q000188:drug therapy* / Q000209:etiology; D041623:Tomography, Optical Coherence
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab